Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

180.53 +3.47 (+1.96%)
Streaming Delayed Price Updated: 2:57 PM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
71 72 Next >
Six Weeks In, AI Outpaces Wall Street's Elite: The ChatGPT Challenge
Via Benzinga
What Will AbbVie Buy Next?
Two mid-cap drugmakers stand out as logical targets for AbbVie. 
Via The Motley Fool
Genmab/AbbVie's Blood Cancer Treatment Shows 82% Response Rate In Pretreated Follicular Lymphoma Patients
Genmab A/S (NASDAQ: GMAB) and AbbVie Inc (NYSE: ABBV) have announced topline results from the follicular lymphoma (FL) cohort of the phase 1/2 EPCORE NHL-1 clinical trial evaluating epcoritamab... 
Via Benzinga
7 Stocks That Every 40-Year-Old Should Buy Today
Having reached the halfway point in life, make your market moves count with the best investments for 40-year-olds. 
Via InvestorPlace
3 Penny Stocks with Multibagger Potential for the Second Half of 2023
If you have patience and a high risk tolerance, here are three penny stocks to watch in 2023 for their multibagger potential. 
Via InvestorPlace
Here's How Much $1000 Invested In AbbVie 10 Years Ago Would Be Worth Today
Via Benzinga
2 No-Brainer Healthcare Stocks to Buy Right Now
Don't bet against these companies. 
Via The Motley Fool
Why Mutual Fund Darling And Top 1% Stock MoonLake Immunotherapeutics Nearly Doubled
The company is treating a painful skin condition and could go up against AbbVie. 
Via Investor's Business Daily
Why CollPlant Biotechnologies Stock Is Trading Higher
CollPlant Biotechnologies Ltd (NASDAQ: CLGN) shares are trading higher Monday after the company announced it achieved a milestone in its product collaboration agreement with AbbVie Inc (NYSE: 
Via Benzinga
Check Out 3 Health Care Stocks With Over 4% Dividend Yields From Wall Street's Most Accurate Analysts
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
1 Phenomenal High-Yield Dividend Stock You Can Buy and Hold Forever
Few high-yield dividend stocks offer all that this one does. 
Via The Motley Fool
4 Stocks That Can Turn $100,000 Into $500,000 by the Time You Retire
Buy 'em and then just get out of the way. Time and these companies' long-term strength will take care of the rest. 
Via The Motley Fool
Cramer Says Datadog Will 'Put Up Some Good Numbers,' And 9 More Stock Takes From 'Mad Money' Host
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Cummins (NYSE: CMI) is a buy. 
Via Benzinga
Alleged Industrial Espionage Makes an Interesting Story
We also chat about Vertex Pharmaceuticals and its role at the center of cystic fibrosis treatment. 
Via The Motley Fool
Biotech And Healthcare Stocks Lagging
Healthcare is a laggard with XLV down YTD but UNH is still a core position. 
Via Talk Markets
RegenXbio's Potential Blockbuster: Analyst is Bullish On Stock Citing Potential Gains From AAV Gene Therapies Resurgence
Baird has initiated coverage on RegenXbio Inc (NASDAQ: RGNX) with an Outperform rating and a  
Via Benzinga
Ready for a Rebound: 7 Blue-Chips Set to Regain Their Market Mojo
Although blue-chip stocks to buy have a reputation for being slow and lumbering, these discounted ideas could swing higher. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Vanguard’s High Dividend Yield (VYM) ETFs Q2 Dividend – Growth
This ETF has been around for almost 20 years and boasts a very low 0.06% expense ratio. 
Via Talk Markets
Why Investors Should Care About Novartis' Latest Label Expansion -- It Could Mean Billions
An immunology drug of the Swiss pharmaceutical giant was approved for yet another indication in the European Union. 
Via The Motley Fool
Unlock the Potential of These 7 Cash-Flow Machines
Here are seven high cash flow stocks that provide investors with both growth and value under any economic conditions. 
Via InvestorPlace
This Biotech Is About to Eat AbbVie's Market Share, but Is It a Buy?
Coherus' biosimilar to Humira could catapult the company to success. 
Via The Motley Fool
AbbVie Touts Promising Results For Risankizumab For Ulcerative Colitis Maintenance
AbbVie Inc (NYSE: ABBV) announced top-line results from the COMMAND Phase 3 maintenance study, showing risankizumab (Skyrizi) achieved the primary endpoint of clinical remission at week 52, as well as... 
Via Benzinga
AbbVie vs Coherus: Dispute Emerges over Upcoming Launch of Low-Cost Biosimilar, Yusimry
AbbVie Inc (NYSE: ABBV) has challenged Coherus BioSciences Inc (NASDAQ: CHRS), alleging Coherus breached its settlement and license agreement after it announced its plans to launch Yusimry, a... 
Via Benzinga
AbbVie Says BeiGene's Flagship Blood Cancer Drug Infringes Imbruvica Patent
BeiGene Ltd (NASDAQ: BGNE) says it is aware that Pharmacyclics LLC has filed a complaint alleging that BeiGene's blood cancer therapy Brukinsa (zanubrutinib) infringes a Pharmacyclics  
Via Benzinga
AbbVie, Deere And A Major Chipmaker Set To Win In AI: CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Bryn Talkington of Requisite Capital Management said AbbVie Inc. 
Via Benzinga
Tuesday Talk: Not Clear Yet
It is not yet clear if the Fed will raise rates by a quarter point or engage in a rate hike pause, at tomorrow's FOMC meeting. The current reading on FedWatch is 79.2% pro-pause. 
Via Talk Markets
High-Yield And Attractively Valued Dividend Stocks
A look at some of the high dividend yields that are available currently, which provide both a solid income and appreciation potential. 
Via Talk Markets
Negotiation or Coercion? Big Pharma and US Chamber of Commerce Tackle Government on Drug Prices
The U.S. Chamber of Commerce has filed a lawsuit against the federal government, challenging a recent law that grants Medicare the authority to negotiate drug prices with pharmaceutical companies. 
Via Benzinga
XPeng's New EV Is a Hit, but This Biotech Stock Is Leaving It in the Dust
Find out more about two big winners Monday morning. 
Via The Motley Fool
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
71 72 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.